Light Sciences Starts BPH Trial
Luke Timmerman8/18/09
Light Sciences Oncology, the Bellevue, WA-based developer of cancer treatments, said today it has started enrolling patients in a mid-stage clinical trial of its light-activated drug for men with benign prostatic hyperplasia (BPH). The condition, sometimes known as enlarged prostate, is characterized by frequent urination, urgency to urinate, and getting up at night to go. The company’s treatment is designed to use a light-emitting diode, threaded inside the affected tissue, to activate a drug called talaporfin sodium (Aptocine) within its wavelength. The treatment is also in the final stage of clinical trials as a treatment for liver cancer.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
